Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 1/20 | 0.58 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | NR2C2 | P49116 | 2/20 | 0.49 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276365 | 0.90 | DDR1 (0.70) | DDR1RAD52NR2C2BTK | |
| SCHEMBL2280492 | 0.88 | DDR1 (0.46) | DDR1RAD52NR2C2HTT | |
| SCHEMBL22457387 | 0.84 | DDR1 (0.58) | DDR1RAD52NR2C2BTKHTT | |
| SCHEMBL12518252 | 0.83 | DDR1 (0.63) | DDR1RAD52 | |
| SCHEMBL2282782 | 0.83 | DDR1 (0.78) | DDR1RAD52ATM | |
| SCHEMBL2278943 | 0.81 | DDR1 (0.65) | DDR1RAD52ATM | |
| SCHEMBL2276363 | 0.80 | DDR1 (0.53) | DDR1RAD52NR2C2 | |
| SCHEMBL13571708 | 0.79 | DDR1 (0.56) | DDR1RAD52HTTMAPK1ATM | |
| SCHEMBL17208712 | 0.76 | BRAF (0.67) | DDR1 | |
| SCHEMBL2280193 | 0.75 | RAD52 (0.75) | DDR1RAD52NR2C2BTKHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| EP-2937345-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-9358231-B2 | Type II RAF kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-06-11 | — | — | US | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| EP-2519517-B1 | TYPE II RAF KINASE INHIBITORS | DANA FARBER CANCER INST INC (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| EP-2519517-A2 | TYPE II RAF KINASE INHIBITORS | Dana-Farber Cancer Institute, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090738-A2 | TYPE II RAF KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | DDR1 1181/4885RAD52 1193/4885NR2C2 1110/4885 |
| US-20150157629-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | DDR1 1181/4885RAD52 1193/4885NR2C2 1110/4885 |
| US-20200297721-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | DDR1 1181/4885RAD52 1193/4885NR2C2 1110/4885 |
| US-20160046636-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | DDR1 1181/4885RAD52 1193/4885NR2C2 1110/4885 |
| US-20130040949-A1 | TYPE II RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | DDR1 1181/4885RAD52 1193/4885NR2C2 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.